Evaluating linaclotide for the treatment of functional constipation in children and adolescents

Pediatric functional constipation is a highly prevalent disorder associated with significant morbidity and impaired quality of life. Despite widespread use of osmotic and stimulant laxatives, a substantial proportion of children remain symptomatic, highlighting an unmet need for novel therapies.

This review provides an overview of the mechanism of action, pharmacokinetics, safety, and clinical efficacy of linaclotide for the treatment of functional constipation in children. Evidence from phase 2 dose-finding studies, a pivotal phase 3 randomized controlled trial, and real-world data is summarized. Prior pediatric experience with other prosecretory and prokinetic agents is discussed to contextualize the current therapeutic landscape. A focused literature review was conducted using PubMed/MEDLINE and regulatory sources (U.S. Food and Drug Administration [FDA]), prioritizing pediatric clinical trials and observational studies evaluating linaclotide in functional constipation.

Linaclotide may represent a mechanism-based therapeutic option for pediatric patients with functional constipation who remain symptomatic despite optimized conventional therapy. By targeting guanylate cyclase-C-mediated epithelial secretion, linaclotide is associated with improvements in bowel habits and a predominantly gastrointestinal safety profile. However, the pediatric evidence base remains relatively limited, and further studies are needed to define long-term outcomes, predictors of response, and its role within treatment algorithms.